CMS payment reform proposals could significantly benefit Organogenesis's products, which are tied to FDA classifications.
2 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CMS payment reform proposals could significantly benefit Organogenesis's products, which are tied to FDA classifications.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Organogenesis (United States)
company in Canton, United States
Nothing else this week.
-
Centers for Medicare and Medicaid Services
United States federal agency
Nothing else this week.
Coverage
Newest first; wire copies grouped- GuruFocus.comOrganogenesis Holdings Inc (ORGO) Q2 2025 Earnings Call Highlights: Navigating Market ... Release Date: August 07, 2025 For the complete transcript of the earnings call, please refer to the full earn
- GlobeNewswireOrganogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation CANTON, Mass., July 15, 2025